Trelagliptin,Markets and News,API,Trelagliptin,865759-25-7,ANQING CHICO PHARMACEUTICAL

Abstract

Trelagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor utilized in the treatment of type 2 diabetes mellitus. Developed by Takeda Pharmaceutical Company, it offers a unique once-weekly dosing regimen. This paper provides a comprehensive overview of trelagliptin, including its chemical properties, development timeline, market presence, and competitive landscape.

Keywords

Trelagliptin, DPP-4 inhibitor, type 2 diabetes mellitus, chemical properties, market analysis, global sales, generics.

Introduction

Trelagliptin, marketed under the brand name Zafatek, is an oral medication prescribed for the management of type 2 diabetes mellitus. As a selective DPP-4 inhibitor, it enhances insulin secretion and inhibits glucagon release, thereby improving glycemic control. Notably, trelagliptin is administered once weekly, offering a convenient alternative to daily DPP-4 inhibitors.

Chemical Properties

The chemical formula of trelagliptin is C18H20FN5O2, with a molar mass of approximately 357.39 g·mol−1. Its IUPAC name is 2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorobenzonitrile. Chemically, it is a fluorinated derivative of alogliptin, designed to provide sustained DPP-4 inhibition suitable for weekly dosing.

Development and Approval Timeline

Developed by Takeda Pharmaceutical Company, trelagliptin was approved for use in Japan in March 2015 under the trade name Zafatek. The development process involved formulating trelagliptin as the succinate salt. Takeda chose not to pursue approval in the United States and European Union due to high costs associated with required clinical studies.

Time on the Market

Since its approval in 2015, trelagliptin has been available in Japan for nearly a decade. Its sustained presence indicates acceptance among healthcare providers and patients, particularly for those seeking a weekly dosing option.

Global Sales and Market Competition

While specific global sales figures for trelagliptin are not publicly available, its market presence in Japan positions it within a competitive landscape of DPP-4 inhibitors, including daily options like alogliptin, sitagliptin, and linagliptin. The availability of both daily and weekly formulations provides patients and healthcare providers with choices tailored to treatment preferences and needs.

Generics and Related Developments

As of now, trelagliptin remains under patent protection, with no generic formulations available. The introduction of generics would likely increase accessibility and reduce costs, aligning with global efforts to make diabetes treatments more affordable.

Conclusion

Trelagliptin exemplifies innovation in diabetes pharmacotherapy, offering a convenient once-weekly dosing option for patients with type 2 diabetes mellitus. Its chemical design and sustained market presence underscore its role in glycemic control. As the market evolves, the introduction of generics and new formulations may further impact its accessibility and position within the competitive landscape.

Active Pharmaceutical Ingredient
865759-25-7
Trelagliptin, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!

Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.

References or other information
FDA、Wikipedia、Chatgpt、DeepSeek、chemicalbook

If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.